Keywords
Last Name
Institution

Paul Mathew

TitleAssociate Professor
InstitutionTufts Medical Center
DepartmentMedicine
AddressDivision of Hematology/Oncology
Tufts Medical Center
800 Washington Street, Box 245
Boston MA 02111
Phone(617) 636-8483
Fax(617) 636-4627
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Joshi R, Goihberg E, Ren W, Pilichowska M, Mathew P. Proteolytic fragments of fibronectin function as matrikines driving the chemotactic affinity of prostate cancer cells to human bone marrow mesenchymal stromal cells via the a5ß1 integrin. Cell Adh Migr. 2016 Aug 11; 1-11. PMID: 27715399.
      View in: PubMed
    2. Mathew P, Einstein DJ, Ladin K. Against "Healthy Paternalism" at the End of Life-Reply. JAMA Oncol. 2016 Jun 1; 2(6):833. PMID: 27281630.
      View in: PubMed
    3. Einstein DJ, Ladin K, Mathew P. The Ethical Imperative of Healthy Paternalism in Advance Directive Discussions at the End of Life. JAMA Oncol. 2016 Apr 1; 2(4):429-30. PMID: 26914544.
      View in: PubMed
    4. Einstein DJ, Einstein KL, Mathew P. Dying for Advice: Code Status Discussions between Resident Physicians and Patients with Advanced Cancer-A National Survey. J Palliat Med. 2015 Jun; 18(6):535-41. PMID: 25984641.
      View in: PubMed
    5. Mandelin J, Cardó-Vila M, Driessen WH, Mathew P, Navone NM, Lin SH, Logothetis CJ, Rietz AC, Dobroff AS, Proneth B, Sidman RL, Pasqualini R, Arap W. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proc Natl Acad Sci U S A. 2015 Mar 24; 112(12):3776-81. PMID: 25762070.
      View in: PubMed
    6. Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer. 2015 Jan 1; 121(1):69-76. PMID: 25155428.
      View in: PubMed
    7. Mathew PG, Pavlovic JM, Lettich A, Wells RE, Robertson CE, Mullin K, Charleston Iv L, Dodick DW, Schwedt TJ. Education and decision making at the time of triptan prescribing: patient expectations vs actual practice. Headache. 2014 Apr; 54(4):698-708. PMID: 24512184; NIHMSID: NIHMS639464.
      View in: PubMed
    8. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013 Jul 1; 19(13):3621-30. PMID: 23649003; NIHMSID: NIHMS475439.
      View in: PubMed
    9. Rosenberg A, Mathew P. Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor. Expert Opin Investig Drugs. 2013 Jun; 22(6):787-94. PMID: 23540855.
      View in: PubMed
    10. Corn PG, Song DY, Heath E, Maier J, Meyn R, Kuban D, DePetrillo TA, Mathew P. Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study. Int J Radiat Oncol Biol Phys. 2013 Jul 1; 86(3):540-5. PMID: 23541810; NIHMSID: NIHMS541991.
      View in: PubMed
    11. Brooks C, Sheu T, Bridges K, Mason K, Kuban D, Mathew P, Meyn R. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer. Radiat Oncol. 2012; 7:154. PMID: 22967802; PMCID: PMC3494537.
      View in: PubMed
      View in: PubMed Central
    12. Dahabreh IJ, Chung M, Balk EM, Yu WW, Mathew P, Lau J, Ip S. Active surveillance in men with localized prostate cancer: a systematic review. Ann Intern Med. 2012 Apr 17; 156(8):582-90. PMID: 22351515.
      View in: PubMed
    13. Kamat AM, Mathew P. Bladder cancer: imperatives for personalized medicine. Oncology (Williston Park). 2011 Sep; 25(10):951-8, 960. PMID: 22010395.
      View in: PubMed
    14. Lin J, Zahurak M, Beer TM, Ryan CJ, Wilding G, Mathew P, Morris M, Callahan JA, Gordon G, Reich SD, Carducci MA, Antonarakis ES. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. Urol Oncol. 2013 Jul; 31(5):581-8. PMID: 21816640; NIHMSID: NIHMS317539.
      View in: PubMed
    15. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 2012 Jan 1; 118(1):63-71. PMID: 21976132; NIHMSID: NIHMS494060.
      View in: PubMed
    16. Aljumaily R, Mathew P. Optimal management of bone metastases in prostate cancer. Curr Oncol Rep. 2011 Jun; 13(3):222-30. PMID: 21336561.
      View in: PubMed
    17. Mathew P, Wen S, Morita S, Thall PF. Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases. J Interferon Cytokine Res. 2011 Jul; 31(7):539-44. PMID: 21323568; PMCID: PMC3163391.
      View in: PubMed
      View in: PubMed Central
    18. Mathew P, Tannir N, Tu SM, Wen S, Guo CC, Marcott V, Bekele BN, Pagliaro L. Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer Chemother Pharmacol. 2011 Oct; 68(4):889-96. PMID: 21290244.
      View in: PubMed
    19. Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs. 2011 Dec; 29(6):1432-40. PMID: 20336348; NIHMSID: NIHMS196926.
      View in: PubMed
    20. Mathew P, Tannir N, Tu SM, Carter CM, Bekele NB, Pagliaro L. A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother Pharmacol. 2010 Mar; 65(4):811-5. PMID: 20052472.
      View in: PubMed
    21. Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15; 15(22):7099-105. PMID: 19887483; NIHMSID: NIHMS371110.
      View in: PubMed
    22. Morita S, Thall PF, Bekele BN, Mathew P. A Bayesian hierarchical mixture model for platelet derived growth factor receptor phosphorylation to improve estimation of progression-free survival in prostate cancer. J R Stat Soc Ser C Appl Stat. 2009 Sep 3; 59(1):19-34. PMID: 20390057.
      View in: PubMed
    23. Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol. 2009 Jul 10; 27(20):3319-24. PMID: 19414670.
      View in: PubMed
    24. Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, Small EJ. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol. 2009 Jun 10; 27(17):2772-8. PMID: 19349545; PMCID: PMC2698016.
      View in: PubMed
      View in: PubMed Central
    25. Mathew P, Pisters LL, Wood CG, Papadopoulos JN, Williams DL, Thall PF, Wen S, Horne E, Oborn CJ, Langley R, Fidler IJ, Pettaway CA. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol. 2009 Jan; 181(1):81-7; discussion 87. PMID: 19012911.
      View in: PubMed
    26. Jain R, Mathew P, Wood CG, Tannir NM. Sunitinib-induced acute hemolysis without hypertension: a case report. Clin Genitourin Cancer. 2008 Sep; 6(2):122-3. PMID: 18824436.
      View in: PubMed
    27. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest. 2008 Aug; 118(8):2697-710. PMID: 18618013; PMCID: PMC2447924.
      View in: PubMed
      View in: PubMed Central
    28. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol. 2008 Sep; 180(3):867-72; discussion 872. PMID: 18635226; NIHMSID: NIHMS615126.
      View in: PubMed
    29. Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res. 2008 Jun 15; 14(12):3729-36. PMID: 18559590; NIHMSID: NIHMS47853.
      View in: PubMed
    30. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007 Oct 1; 13(19):5816-24. PMID: 17908974.
      View in: PubMed
    31. Mathew P, Dipaola R. Taxane refractory prostate cancer. J Urol. 2007 Sep; 178(3 Pt 2):S36-41. PMID: 17644120.
      View in: PubMed
    32. Mathew P, Logothetis CJ, Dieringer PY, Chen I, Pagliaro LC, Bekele BN, Zhou X, Daliani DD. Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer. 2006 Sep; 5(2):144-9. PMID: 17026803.
      View in: PubMed
    33. Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer. 2006 Aug 1; 107(3):497-505. PMID: 16795067.
      View in: PubMed
    34. Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis C, Mathew P, Wang X, Do KA, Fan D, Fidler IJ. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst. 2006 Jun 7; 98(11):783-93. PMID: 16757703.
      View in: PubMed
    35. Rodney A, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC. Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer. 2006 May 15; 106(10):2143-7. PMID: 16598751.
      View in: PubMed
    36. Mathew P, Vakar-Lopez F, Troncoso P. Protracted remission of metastatic epithelioid angiosarcoma with weekly infusion of doxorubicin, paclitaxel, and cisplatin. Lancet Oncol. 2006 Jan; 7(1):92-3. PMID: 16389189.
      View in: PubMed
    37. Kim SJ, Uehara H, Yazici S, He J, Langley RR, Mathew P, Fan D, Fidler IJ. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res. 2005 May 1; 65(9):3707-15. PMID: 15867366.
      View in: PubMed
    38. Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ, Logothetis C. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol. 2004 Aug 15; 22(16):3323-9. PMID: 15310776.
      View in: PubMed
    39. Mathew P, Fidler IJ, Logothetis CJ. Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin Oncol. 2004 Apr; 31(2 Suppl 6):24-9. PMID: 15176001.
      View in: PubMed
    40. Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, Fidler IJ. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst. 2003 Mar 19; 95(6):458-70. PMID: 12644539.
      View in: PubMed
    Mathew's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _
    This website was supported by the National Center for Research Resources Award Number UL1RR025752 and the National Center for Advancing Translational Sciences, National Institutes of Health, Award Numbers UL1TR000073 and UL1TR001064. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

    Disclaimer | Tufts University | Tufts CTSI 2015